Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 30Terminated 12Recruiting 9Active not recruiting 4Withdrawn 3Unknown 2Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 22Lymphoma, Large B-Cell, Diffuse 16Recurrence 7Neoplasms, Plasma Cell 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Diseases 2Colorectal Neoplasms 2Blood Protein Disorders 2Sezary Syndrome 1Renal Insufficiency 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 36Etoposide 25Vincristine 24Cytarabine 21Doxorubicin 19Rituximab 17Radiotherapy 17Peripheral Blood Stem Cell Transplantation 16Melphalan 16Prednisolone 14Methotrexate 14Filgrastim 13fludarabine phosphate 11Prednisone 11Dexamethasone 11Carmustine 9Bleomycin 9pegylated granulocyte colony-stimulating factor 8Cyclosporine 8Busulfan 8Ifosfamide 7Cisplatin 7sargramostim 6fludarabine 6Vinblastine 6Mitoxantrone 6Methylprednisolone 6Gemcitabine 6Chlorambucil 6Antilymphocyte Serum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lymphoma × Lenalidomide × Clear all
NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Keymed Biosciences Co.Ltd

Phase 1 Unknown
87 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
70 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡